<DOC>
	<DOC>NCT02772419</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy and safety of SC administrations of Benralizumab or Placebo in the subjects with Eosinophilic Chronic Rhinosinusitis in a multicenter, randomized, double-blind, placebo-controlled study. The pharmacokinetics and immunogenicity will be assessed secondarily.</brief_summary>
	<brief_title>Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis</brief_title>
	<detailed_description>Screening Period (maximum 4 weeks) , Randomized Treatment Period (24 weeks)</detailed_description>
	<mesh_term>Sinusitis</mesh_term>
	<criteria>Patients 20 years to 75 years of age Eosinophilic chronic rhinosinusitis with a total score of ≥ 11 according to the diagnosis of eosinophilic chronic rhinosinusitis at enrollment A minimum bilateral nasal polyp score of 3 out of the maximum score of 8 (with a score of at least 1 out of the maximum score of 4 for each nostril) at screening and at enrollment Weight of ≥ 40 kg at screening A SinoNasal Outcome Test22 (SNOT22) score of &lt; 7 at enrollment Any nasal surgery (including polypectomy) within 1 year prior to the date of consent Hospitalization for ≥ 24 hours for treatment of asthma exacerbation, within 12 weeks prior to the date of consent Exposure to any commercially available (e.g., omalizumab) or investigational biologic agent within 16 weeks or 5 halflives prior to enrollment, whichever is longer Use of systemic corticosteroids (including oral corticosteroids) or corticosteroid nasal solution (except spraying) within 4 weeks prior to enrollment or planned use of such medications during the doubleblind period Prior treatment with benralizumab</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>